The administration of tumor vaccine enabled tumor control at lower CAR-T cell doses (98).Similar results have been shown in other studies using WT1-specific CAR-T cells combined with DC vaccine pulsed with WT1236Y peptide (99) and CMV/CD19 bispecific T cells combined with CMV peptide vaccine (100). This evidence concerns the gene CD19 and neoplasm.